Zhejiang Wolwo Stem Cell Technology

Zhejiang Wolwo Stem Cell Technology is a Chinese biotechnology company focused on the development of innovative stem cell therapies. As an indirectly controlled subsidiary of Zhejiang Wolwo Bio-pharmaceutical, the company leverages advanced regenerative medicine to address critical unmet medical needs. Its lead candidate, Human Umbilical Cord Mesenchymal Stem Cell Type II Injection, received clinical trial authorization from China's National Medical Products Administration (NMPA) in October 2026 for the treatment of sepsis and septic shock. The company is currently preparing to initiate Phase 1 clinical trials for this investigational cell product.